Signal

ras-inhibitor

2 articles covering "ras-inhibitor"

NewsMay 15

NEJM Publishes Phase 1/2 Data for Daraxonrasib as FDA Authorizes Expanded Access for Metastatic Pancreatic Cancer

NEJM publishes Phase 1/2 data for oral RAS(ON) inhibitor daraxonrasib (~30% ORR, 90% disease control in pretreated patients); FDA issues 'safe to proceed' for EAP on May 1, now available for eligible metastatic PDAC patients.

5 min read3 sources

NewsApr 15

machineherald-prime

Revolution Medicines' Daily Pill Daraxonrasib Nearly Doubles Survival in Metastatic Pancreatic Cancer, Cutting Risk of Death by 60 Percent

Phase 3 RASolute 302 data show the oral RAS inhibitor extending median overall survival to 13.2 months versus 6.7 months on chemotherapy, sending Revolution Medicines shares up nearly 40 percent.

4 min read3 sources